NEWSWIRETODAY Press Release& Newswire Distribution | HOME
PRTODAY / NewswireToday press release distribution service network
Agency / Source: SmallCapReview

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour! Initiates Coverage of Biosante Pharmaceuticals and Given Imaging -, A leading site for news and information on small caps, penny stocks and microcaps is adding Biosante Pharmaceuticals (BPAX) and Given Imaging (GIVN) to its list of stocks Initiates Coverage of Biosante Pharmaceuticals and Given Imaging


NewswireTODAY - /newswire/ - Winston-Salem, NC, United States, 2012/02/15 -, A leading site for news and information on small caps, penny stocks and microcaps is adding Biosante Pharmaceuticals (BPAX) and Given Imaging (GIVN) to its list of stocks "On the Radar".

Your Banner Ad Here instead - Showing along with ALL Articles covering Brokerage / Trading Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


BioSante Pharmaceuticals (BPAX) is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante's products include LibiGel (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD), specifically hypoactive sexual desire disorder (HSDD), which is in Phase III clinical development according to a U.S. Food and Drug Administration (FDA) Special Protocol Assessment (SPA).

BioSante's first FDA-approved product is Elestrin (estradiol gel) indicated for the treatment of hot flashes associated with menopause, marketed in the U.S. by Azur Pharma, BioSante's licensee. BioSante also is developing a portfolio of cancer vaccines, four of which have been granted Orphan Drug designation, and are currently in several Phase I and Phase II clinical trials. Other BioSante products are Bio-T-Gel, a testosterone gel for male hypogonadism, for which a New Drug Application (NDA) is pending, licensed to Teva Pharmaceuticals, and an oral contraceptive in Phase II clinical development.

BPAX Investor Highlights

BPAX won U.S. clearance to sell Bio-T-Gel, a testosterone replacement therapy for men. Teva will market Bio-T-Gel for men with low testosterone. BioSante, the original developer of Bio-T-Gel, estimates the market for male testosterone products is more than $1.2 billion in the U.S., where hypogonadism affects as many as 5 million men. BioSante licensed the gel to Teva, the world’s largest generic-drug maker, and will receive milestone payments and royalties when the drug is commercialized.

Announced that the independent Data Monitoring Committee (DMC) has completed the eighth unblinded review of the LibiGel Phase III cardiovascular and breast cancer safety study, which has completed enrollment of subjects. The independent DMC has recommended that the LibiGel safety study should continue as per the FDA-agreed protocol, without modifications.

As of December 31, 2011, BioSante had approximately $57 million in cash and cash equivalents and $20.8 million in principal amount of convertible notes outstanding, due on May 1, 2013. The projected burn rate for 2012 is approximately $2.5 million per month, assuming the LibiGel safety study continues.

BioSante continues to analyze the LibiGel data from the two pivotal Phase III efficacy trials first reported on December 14, 2011. LibiGel is in development for the treatment of female sexual dysfunction (FSD), specifically, hypoactive sexual desire disorder (HSDD) in postmenopausal women, for which there is no FDA-approved product.

BioSante’s cancer vaccines are in development for the treatment of several different types of cancer including melanoma, pancreatic, breast and prostate cancer. Currently, there are 17 Phase I and Phase II clinical studies ongoing, primarily being conducted at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center in Baltimore, Maryland.

Given Imaging (GIVN) together with its subsidiaries, engages in the development, manufacture, and marketing of diagnostic products for the visualization and detection of gastrointestinal tract disorders. The company provides Given System, a wireless imaging system that uses PillCam capsules for visual examination of the gastrointestinal tract. These PillCam capsules when ingested by patients and move naturally through the gastrointestinal tract, and wirelessly transmitting to a portable recorder, enabling the gastroenterologist to view video, images, and data on a computer workstation.

The company also offers PillCam SB capsule for visualization and detection of abnormalities of the small bowel; PillCam ESO capsule for visualizing the esophageal mucosa; PillCam COLON, a video capsule for patients who have received incomplete colonoscopy; and Agile Patency capsule and system, which is a dissolvable capsule that enables physicians to determine whether there are obstructions or strictures in the gastrointestinal tract that prevent the passage of its PillCam Small Bowel capsule. In addition, it provides data recorder, sensor array, and SensorBelt; and RAPID software that processes the capsule data stored in the data recorder to the visual presentation of data. Further, the company offers non-imaging products, such as Bravo pH monitoring system, a wireless catheter-free pH test for gastro esophageal reflux disease; catheter-based AccuTrac pH and impedance monitoring system, and the Digitrapper pH-only monitoring system; and the ManoScan system that obtains mapping of pressures levels and optionally impedance levels, within organs of the human gastrointestinal tract primarily the esophagus and anorectal organs.

It markets and sells its products through local distributors or representatives, as well as directly primarily in the United States, Australia, Canada, France, Germany, Japan, and Israel.

GIVN Investor Highlights

Fourth Quarter 2011 Revenues Increase 8% to $48.5 Million; Fourth Quarter Non-GAAP and GAAP EPS $0.25 and $0.18, Respectively; Fiscal Year 2011 Revenues Increase 13% to $178.0 Million; 2011 GAAP Net Income Increases 41% to $12 Million, or $0.39 per Share; 2011 Non-GAAP Net Income Increases 2% to $20.1 Million, or $0.65 per Share.

Cash and cash equivalents, short-term investments and marketable securities on December 31, 2011 totaled $105 million. Net cash provided by operating activities in the fourth quarter was $10.1 million.

In January, Given Imaging initiated direct commercial operations in Brazil and established an office in São Paulo. Sales activities will be managed by the leadership team from its key distribution partner in Brazil since 2002.

In November, Given Imaging initiated a pivotal trial for PillCam COLON 2 in Japan intended to support the Company's planned regulatory submission to Japan's Pharmaceuticals and Medical Devices Agency in the middle of 2012.

Announced that approximately 700 patients have been enrolled in the Company's PillCam COLON 2 pivotal trial, and more than 500 patients have ingested PillCam COLON 2 in the trial.

To learn more about BPAX and GIVN visit

Features available at include in-depth profiles of select Small-Cap/Penny Stocks as well as the most comprehensive and up to date news available on the small-cap market.

No investor should assume that reliance on the views, opinions or recommendations contained herein will produce profitable results. Nothing within our site should be construed as an offer or solicitation to buy or sell products or securities. The companies we profile may lack an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. has not been compensated by any of the above mentioned companies nor do we hold in equity positions at this time.

Copyright SmallCapReview. is a leading site for news on small-caps, penny stocks and microcaps. SmallCapReview has built a loyal opt-in following for their investor products by providing a newsletter at no cost, sent to subscribers, highlighting select stocks in play.

Your Banner Ad Here instead - Showing along with ALL Articles covering Brokerage / Trading Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


Agency / Source: SmallCapReview


Availability: All Regions (Including Int'l)


Traffic Booster: [/] Quick NewswireToday Visibility Checker


Distribution / Indexing: [+]

# # #
  Your Banner Ad showing on ALL
Brokerage / Trading articles,
CATCH Visitors via Your Competitors Announcements! Initiates Coverage of Biosante Pharmaceuticals and Given Imaging

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
Contact: Thomas Englebert - 
336-838-5005 editor[.]
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any SmallCapReview securities in any jurisdiction including any other companies listed or named in this release.

Brokerage / Trading via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Read Latest Articles From SmallCapReview / Company Profile

Read Brokerage / Trading Most Recent Related Newswires:

Heritage Brokerage Solved Compliance Issues Using AdvisorVault As their Chosen17a-4 D3P Partner
OANDA Partners with AdvantageGo to Help Insurance Companies Mitigate Policy Risk
SRMEX's Vice Chairman Eikichi Hirano About the Gradual Expansion of Capital Market
Xtrade Wins Best Broker in the Middle East Award
Russian Foreign Trade Reports on Russian Trade with North American Countries Q1 2016
DarkMaindFX Introduces the Beta Version of its Economic Indicator Services
Hermes International Expo to Celebrate 25th Anniversary in Delaware County
GoldSilver Central Approved As Singapore Bullion Market Association Member
OANDA Acquires Tradestation Forex Accounts
[TYPO FOUND BY SYSTEM] Beeline Broking Ltd Launches 'Tailor Made Brokerage Plan' Announces Key Features - Makes it the Best Binary Options Signals Service
Binary Options Signals from Helps Traders to Get Higher Win-Rate
/RC/ Van Ecker Couder Associates Announce Expansion Program
/RC/ Voth Nixon Group Bolsters Deferred Income Annuity
Grant Becker Associates Chalks Up Another Successful Year of CSR Activities

Boost Your Social Network
& Crowdfunding Campaigns

NewswireToday Celebrates 10 Years in Business


Visit  Encounter Church FW

Visit  RightITnow, Inc.

  ©2005-2023 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
PRTODAY & NewswireTODAY are proudly NOT affiliated with USA TODAY (